

41

STRIP AGA TEST: A RAPID AND ACCURATE METHOD IN  
SCREENING FOR COELIAC DISEASE.

T. Not, A. Ventura, M. Bittolo\*, G. Torre and M. Andolina

Clinica Pediatrica and Dipart. di Biologia, Univ. Trieste, ITALY  
Antiflagellin antibodies (AGA) are a useful tool in screening for  
Coeliac Disease (CD). Anyway, this test requires a rather speciali-  
zed laboratory, a venous blood sample and about one week in order  
to obtain the result for the family paediatrician. We developed  
and evaluated a dot immunobinding assay to detect antiflagellin IgG  
and IgA antibodies in a single drop of whole blood. The method is  
based on the absorption of alfa-flagellin as a spot on to nitro-  
cellulose sheets, who are immobilized on plastic strips. The strips  
were incubated 30' with patient sample, and 30' with alkaline  
phosphatase conjugate antihuman (IgA and IgG) antibodies. After short  
incubation (15') with the substrate solution, the strip was dried and  
finally examined for the results, which are expressed by a colo-  
rimetric reaction. Twenty patients with CD (10 with active disease,  
10 during gluten free diet (GFD)), 11 children with other gastro-  
intestinal diseases (8 IBD, 1 autoimmune chronic diarrhoea, 1 con-  
genital microvillous atrophy, 1 unexplained chronic diarrhoea) and  
35 healthy controls were examined with both strip AGA test and the  
classic ELISA test for AGA. The results are summarized as follows:

PATIENTS	n°	DOT IgA	IgG	ELISA IgA	IgG
CD untreated	10	+	+	+	+
CD on GFD	5	+	+	+	+
	5	-	-	-	-
GASTROINT. CONTR.	5	+	+	+	+
	2	-	+	-	+
	3	-	-	-	-
HEALTHY CONTROLS	35	-	-	-	-

The method showed good correspondence with ELISA AGA test: the pro-  
cedure is quick and simple and does not require any costly equip-  
ment. We think that this "Strip AGA test" could be very convenient  
both for screening and for the follow-up of CD. This test could  
also be useful in population and/or family screening for C.D.

42

HEPATOBIILIARY SCANNING IN PATIENTS WITH CYSTIC FIBROSIS AND LIVER  
DISEASE BEFORE AND AFTER URSODEOXYCHOLIC ACID (UDCA) THERAPY.

C. Colombo, M.R. Castellani\*, E. Seregni\*, F.G. Apostolo, S. Forman, A. Giunta

Dept. Pediatrics, University of Milan, \*Nuclear Medicine Div. National Cancer Inst. ITALY

It has recently been indicated that 96% of patients with liver disease secondary to  
Cystic Fibrosis (CF) showed evidence of common bile duct stenosis on hepatobiliary  
scanning (Gaskin et Al: N. Eng. J. Med. 318:340, 1988). We performed IDA scan pre and 10 -  
12 months post administration of the hydrophilic and choleric UDCA (15mg/Kg/day)  
in 8 children with CF related liver disease. Morphological pattern as well as func-  
tional parameters (% of hepatic wash-out, time of visualization of the intestine) were  
evaluated. At baseline, evidence of severe biliary obstruction was found in 2 cases,  
striking visualization of secondary and tertiary bile ducts in 5 and dilatation of  
common bile duct in 4; an enlarged gallbladder with delayed emptying was present in  
2 patients and in 3 the gallbladder could not be visualized. After UDCA therapy, mor-  
phologic appearance at IDA scan improved markedly in all patients: none showed evi-  
dence of biliary obstruction, dilatation of common bile duct and intrahepatic ducts  
was substantially reduced and in all cases the gallbladder was visualized and appea-  
red to empty normally. Mean % of hepatic wash-out decreased from 50 ± 21 min. at ba-  
seline to 36.0 ± 18 min. after therapy and mean time of visualization of the intesti-  
ne decreased from 46.8 ± 40.8 min. to 17.5 ± 9.3 min. after UDCA. In all patients on  
UDCA liver function tests improved significantly and enrichment of the biliary bile  
acid pool with UDCA (from 4.8 ± 2.2% to 28.5 ± 9.6%) occurred.

The modifications observed after UDCA therapy suggest that inspissated secretions  
in CF patients may be responsible for the typical appearance at hepatobiliary scan-  
ning and that the improvement during UDCA may be related to its choleric effect.

43

DO TRANS FATTY ACIDS (TFA) IMPAIR BIOSYNTHESIS OF  
LONG-CHAIN POLYUNSATURATES (LCP) IN MAN?

Berthold Koletzko

Universitäts-Kinderklinik D-4000 Düsseldorf, FRG.

Humans consume large amounts of TFA due to the extensive use of  
hydrogenated fats in food production. TFA consumption is  
considered safe for man, but side effects including impaired  
synthesis of LCP (20 & 22 carbons) have been observed in animal  
studies. We have previously documented materno-fetal transfer of  
TFA in humans. Therefore, we looked for possible effects of TFA  
on LCP status during early life, when LCP modulate tissue growth  
and development. **Methods:** Blood plasma samples were obtained in  
29 clinically well premature infants (gest. age 34.0 ± 1.8 wks.,  
birthwt. 1694 ± 173 g, M ± SD) prior to feeding in the morning of day  
3 post partum, when milk intake was still very low. No infant had  
received fat infusions. Fatty acids in lipid classes were  
determined by high-resolution gas-liquid-chromatography. **Results:**  
Both total TFA and elaidic acid (18:1t), the main dietary TFA,  
were inversely correlated to LCP in plasma lipids. In  
triglycerides, linear correlation coefficients (r) for 18:1t were  
significant (P < 0.05\* & 0.01\*\*) for LCP (n-6-LCP: -0.41\*, n-3-LCP:  
-0.50\*\*, total LCP: -0.55\*\*) and for product substrate ratios of  
LCP biosynthesis (20:4/18:2n-6: -0.47\*\*, 22:6/18:3n-3: -0.50\*\*).  
Similar results were found in other lipid classes for 18:1t and  
total TFA. **Conclusions:** 1. TFA exposure may impair biosynthesis  
of n-6- and n-3-LCP in man. 2. Since the capacity for LCP  
biosynthesis is limited during early life and LCP accretion is  
essential for normal functional development of membrane rich  
tissues (e.g. brain), a high intrauterine TFA exposure may have  
serious risks for fetus and neonate. 3. This observation is the  
first indication of possible untoward effects of TFA in man.

44

LKM-1 ANTIBODY POSITIVE AUTOIMMUNE HEPATITIS IN  
IDENTICAL TWINS: IN VITRO INHIBITION OF THE TARGET  
ANTIGEN CYTOCHROME P450 db1 AND IN VIVO PHENOTYPE

S. Koletzko, H. Löhr, M. Eichelbaum, F. Borchard,  
C. Rittner, K.-H. Meyer zum Büschenfelde, M. Manns

Kinderklinik & Patholog. Institut, Univ. D-4000 Düsseldorf, and  
I. Medizinische Klinik & Rechtsmedizin, Univ. D-6500 Mainz, FRG.

A subgroup of autoimmune type chronic active hepatitis (AI-CAH)  
is associated with LKM-1 autoantibodies. They are directed  
against Cytochrome P450 db1 and inhibit its function in vitro. We  
observed LKM-1 positive AI-CAH and colitis in a 13 year old girl.  
Liver disease responded well to corticosteroids. Father, mother,  
brother, the patient and her identical twin sister were  
investigated for HLA class I-III phenotypes, auto-antibodies, in  
vitro inhibition of P450 db1, and in vivo phenotype for drug  
metabolism (sparteine) mediated by this enzyme. Both twins had  
the autoimmune HLA haplotype A1, B8, DR3, C4A-Q0. While the  
mother is a homozygous extensive metabolizer (EM) (metabolic  
ratio 0.33), the father is a homozygous poor metabolizer (MR  
65.25) and all children are heterozygote EM (MR 1.01, 0.99 &  
1.76). Only the index patient had signs of liver disease and was  
positive for LKM-1 antibodies, and only her serum inhibited P450  
db1 catalysed oxidation of sparteine in vitro up to 90%.  
**Conclusion:** We describe for the first time occurrence of LKM-1  
positive AI-CAH in a pair of identical twins, who were discordant  
for the disease. Since both twins are of the EM metabolizer type,  
i.e. express functionally intact P450 db1, and share the  
autoimmune HLA haplotype, we conclude that environmental factors  
trigger the manifestation of this autoimmune liver disease.

45

PROSTAGLANDINS IN SMALL INTESTINAL MUCOSA OF CHILDREN WITH ACTIVE COELIAC  
DISEASE AND ON A GLUTEN FREE DIET.

M. Bonamico, P. Lionetti, P. Mariani, D. D'Alessandro, P. Triglione, P. Mariani,  
E. Ferrante and G. Ballati

I Paediatric Clinic, II Surgical Clinic, "La Sapienza" University, Rome, Italy.

Enhanced synthesis of Prostaglandins (PGs) has been reported in coeliac disease (CD) and  
a possible involvement of these substances in the pathogenesis of diarrhoea in coeliac  
patients has been supposed. The aim of our study was to evaluate Prostaglandin E2 (PGE2)  
and 6-ketoprostaglandin F1α (6-Keto-PGF1α) synthesis in small intestinal mucosa of three  
groups of patients: group A, consisting of 11 children with active CD and total or  
subtotal mucosal atrophy, group B consisting of 7 children on a gluten free diet for at  
least 1 year with mild villous atrophy or normal intestinal mucosa, group C (control) of 6  
non-coeliac patients with normal intestinal mucosa. Only 6 children from group A had  
chronic diarrhoea while children from group B were asymptomatic. Children from group C  
suffered from failure to thrive; we excluded from this group children who showed  
diarrhoea. The amounts of PGs generated by intestinal mucosa were measured by a standard  
method, using a RIA system. In group A PGE2 generation was significantly higher (2052 ±  
407, Mean ± SE) than in group C (603 ± 140) (p < 0.003). Children from group A with chronic  
diarrhoea and those without this symptom both showed significant higher PGE2 generation  
(2569 ± 687, 1431 ± 171, respectively) than group C (p < 0.02). In group B PGE2 generation  
was higher (1632 ± 567) but not significantly different from group C. 6-Keto-PGF1α  
generation although higher in group A and B than C did not show any statistically  
significant variation. Our results indicate that PGE2 generation in CD is not always  
related to the presence of diarrhoea. Elevated PGs levels in intestinal mucosa in CD may  
be due to both enhanced synthesis and decreased degradation. Alternatively, as  
hypothesized by Branski (J Pediatr Gastroenterol Nutr 3, 672, 1984), it could be the  
expression of an adaptive mechanism. This latter hypothesis could explain our results of  
high PGE2 levels in asymptomatic coeliac children on a gluten free diet. Maybe is necessary  
a long period of diet before to cease this adaptive mechanism.

46

SMALL INTESTINAL TRANSPLANTATION (SIT) IN CHILDREN.

Soulet O., Révillon Y., Jan D., Brousse N., Corf-Bensussan N.,  
Mougenot J.F., De Potter S., Ricour C., Necker Hospital Paris.

After experiments on piglets and rats SIT using Cyclosporine A (CsA) and after  
obtaining consent form from parents, we performed six SIT in children (6mths-  
9yrs) with short gut syndrome on home TPN for 0,5 to 6 years. All but one donor  
and recipients were Isoblood group ABO, with negative cross match reaction. Graft  
were harvested on brain dead neonates (n=2) or children 6-17 yrs. 110 ± 10 cm of  
Jejunum ileum underwent both vascular and luminal washing using Collins (n=3) or  
UW (n=3). After aorta and inferior vena cava anastomosis total ischemic time  
ranged from 1 hr 20 to 6 hr 30. Graft was anastomosed on proximal end; both  
distal graft and own intestine were exteriorized as stomas. Initial  
immunosuppression included solumedrol 2 mg/kg/d and Cyclosporine as a continuous  
infusion for RIA serum levels 200-300 ng/ml. Antilymphoglobuline (ALG) (5  
mg/kg/d) for 14 days were added in the last 4 cases. Systemic antibiotics and  
total decontamination of the graft are associated. The first graft was removed  
after 8 hours for ischemia; the child was discharged on home PN. Early (< 15  
days) or delayed (2-6 mths) acute graft rejection (GR) occurred in all cases. Late  
clinical symptoms included increased ileostomy drainage while histologic pattern  
changed earlier including progressively: T cell infiltrates (CD4+, CD8+, CD25+),  
increased HLA DR expression by crypts enterocytes, villi oedema, destruction of  
crypt and surface epithelium, crypt abscess and finally mucosal sloughing. GR was  
treated with ALG or OKT3 but led to graft removal in 3 cases 3 wks to 6 mths  
after SIT. One graft was removed on the 17th mth because of chronic rejection.  
Four graft were progressively used from the 4th mth tolerating up to 90 % of total  
energy intakes, like in one patient still living with the graft for 10 mths.  
Functional assessment included baryum transit, enzyme activities, and absorption  
tests. Those results show that SIT is possible but depending on important  
immunosuppression. No GVH reaction was observed. GR can be limited by repeated  
immunohistochemical study and early treatment.